Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

Benzinga · 2d ago
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.